Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.See webinar details
Acute oral complications of cancer therapy
Published on February 28, 2017 53 min
Other Talks in the Series: Oral & Maxillofacial Medicine
Sensory and motor deficits
- Dr. Dimitris Malamos
- National Organization of Health Service (IKA), Greece
Soreness and ulcers 1: recurrent ulcers due to aphthae and aphthous-like ulcers
- Prof. Camile Farah
- School of Dentistry - University of Western Australia, Australia
White lesions - oral leukoplakia, a premalignant lesion
- Prof. Palle Holmstrup
- University of Copenhagen, Denmark
Hello, I'm Douglas Peterson, Professor of Oral Medicine in the School of Dental Medicine as well as Co-Chair of the program in Head and Neck Cancer and Oral Oncology at the Neag Comprehensive Cancer Center at UConn Health here in Farmington, Connecticut in the USA. Now, what I'd like to talk with you about today are selected "Acute Oral Complications of Cancer Therapy".
The approach I have taken for today's discussion is to highlight selected clinically significant oral toxicities of cancer treatment. The three toxicities that I've chosen include: acute periodontal infection in the neutropenic cancer patient, acute oral mucosal viral infection, again in the neutropenic cancer patient, and then mucosal injury that's caused either by high-dose chemotherapy or head and neck radiation. Or oral lesions that are being now identified as caused by targeted cancer therapies, such as mTOR inhibitors. These are recently identified lesions over the last few years.
I'd like to recommend the following National Cancer Institute web resource for additional information on today's presentation. This is produced by the National Cancer Institute Physician Data Query Cancer Information program. And the specific website I'd recommend is titled, "Oral complications of chemotherapy and head/neck radiation." The website is listed on this slide. I'm involved in the production of this website that's reviewed by the National Cancer Institute. And we're in the middle of some strategic scientific updates based on some recent advances in the evidence. And there are health professional and patient versions available for your use and your patient's use.